Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2019 – CLL
ASH 2019 – CLL
Venetoclax plus Ibrutinib in Mantle-Cell Lymphoma: 3-Year Study Update
ASH 2019 – CLL
Mantle-cell lymphoma is a relatively aggressive type of non-Hodgkin lymphoma. Results from a study of patients who elected to interrupt treatment with ibrutinib plus venetoclax are presented.
Read More ›
Venetoclax and Ibrutinib for Relapsed and Refractory CLL: Interim Analysis of MRD Testing
ASH 2019 – CLL
Targeted drug treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) are given indefinitely: either until disease progression or until side effects are no longer manageable. A key question is whether oncologists can use results of minimal residual disease (MRD) testing to determine if patients can take a break from treatment with targeted drugs.
Read More ›
Acalabrutinib for Relapsed and Refractory CLL and SLL
ASH 2019 – CLL
Updated analysis of ASCEND trial showed that acalabrutinib, a highly selective Bruton tyrosine kinase inhibitor, improves progression-free survival compared with other treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More ›
The iR² Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ASH 2019 – CLL
Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant.
Read More ›
Triple-Drug Combination for Relapsed and Refractory CLL
ASH 2019 – CLL
A study evaluating the safety and efficacy of a new 3-drug combination is underway in patients with relapsed and refractory chronic lymphocytic leukemia (CLL).
Read More ›
Ibrutinib Combined with Venetoclax for First-Line Treatment of CLL and SLL
ASH 2019 – CLL
Results from a study of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to see if treatment with ibrutinib plus venetoclax could be stopped for those who have a good response.
Read More ›
Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma
ASH 2019 – Wrap-up
,
ASH 2019 – CLL
Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma.
Read More ›
Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial
ASH 2019 – Post Wrap-Up
,
ASH 2019 – CLL
Extended follow-up of the E1912 trial showed a significant advantage for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib + rituximab compared with those treated with fludarabine, cyclophosphamide, and rituximab (FCR).
Read More ›
Bruton Tyrosine Kinase Inhibitor Zanubrutinib in Patients with CLL and SLL
ASH 2019 – CLL
Zanubrutinib is an investigational, next-generation Bruton tyrosine kinase inhibitor. It has been tested in previously untreated patients with del(17p) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who are enrolled in the SEQUOIA trial.
Read More ›
Venetoclax plus Ibrutinib in Mantle-Cell Lymphoma
ASH 2019 – CLL
An updated analysis of combined or pooled data from studies of ibrutinib. For the first time, a comparison of outcomes with ibrutinib versus patients’ prior treatment regimens for mantle-cell lymphoma is shared.
Read More ›
Page 1 of 4
1
2
3
4
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us